EUVIMEDDescobrir EUVIMED
Open access · CC BY 4.0

Assessment of Donor‐Specific Human Leukocyte Antigen Antibodies Following Pediatric Liver Transplantation: Predictors, Protectors, and Clinical Relevance

Evelien Kanaan, Sinja Ohlsson, Simone Kathemann, Benas Prusinskas, Sofia Tsaka, Falko M Heinemann, Andreas Heinold, Maren Schulze, Lars Pape, Elke Lainka iD

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70390 ↗

At a glance

Journal article in Clinical Transplantation, 2025. Written by Evelien Kanaan and 9 co-authors. Institution: Department of Pediatrics II, University Children's Hospital, Essen, Germany. Major MEDLINE topics: Liver Transplantation, HLA Antigens, Graft Rejection, Isoantibodies. Cited 2 times so far (Crossref); 49 references. The full text is freely available (open access, CC BY 4.0).

ResumoSubjectsDados bibliográficosCiteRelated studies

Abstract (original language)

Background

Following pediatric liver transplantation (pLT), the significance and management of donor‐specific antibodies (DSA) against human leukocyte antigen (HLA) remain undefined. The aim of this single‐center study was to investigate the occurrence of DSA, their clinical impact on predictors for and protectors against DSA. Patients and Methods We compared anti‐HLA DSA (cutoff for mean fluorescence intensity (MFI) ≥ 1000), clinical and laboratory results and outcome in a routine (RG, n = 142, standard DSA testing) and a hepatopathy group (HG, n = 19, DSA testing following indeterminate hepatopathy) in 161 pLT patients, treated 2000–2021, retrospectively.

Results

40% of RG and 32% of HG patients were DSA+ (39% of all patients, of which 13% with antibody‐mediated rejection [AMR]). Most frequent DSA subtypes were HLA‐DQ3, ‐DQ1, ‐DQ2 in RG and HLA‐DQ2, ‐DR15 in HG. MFI was higher for anti‐HLA II DSA (15 257 DSA+ vs. 5500 DSA−, p = 0.003), especially with AMR (21 000 DSA+ with AMR vs. 14 584 DSA+ without AMR, p = 0.042). Predictors for DSA included age at pLT, re‐pLT, and cystic fibrosis. Living donation and cold ischemia time

Subjects

MeSH terms (MEDLINE)

Liver TransplantationHLA AntigensGraft RejectionIsoantibodiesTissue DonorsPostoperative ComplicationsHumansMaleChildFemaleRetrospective StudiesGraft SurvivalFollow-Up StudiesPrognosisChild, PreschoolInfantAdolescentRisk FactorsSurvival RateClinical Relevance

Author keywords

antibody‐mediated rejectiondonor‐specific antibodieshuman leukocyte antigen antibodiespediatric liver transplantation

Substances

HLA AntigensIsoantibodies

Authors and institutions

  • Department of Pediatrics II, University Children's Hospital, Essen, Germany.
  • Institute for Transfusion Medicine, Transplantation Diagnostic, University Hospital, Essen, Germany.
  • Department of General, Visceral- and Transplant Surgery, University Hospital, Essen, Germany.

ORCID profiles: Elke Lainka

Cite

APA

Kanaan, E., Ohlsson, S., Kathemann, S., Prusinskas, B., Tsaka, S., Heinemann, F. M., Heinold, A., Schulze, M., Pape, L., & Lainka, E. (2025). Assessment of Donor‐Specific Human Leukocyte Antigen Antibodies Following Pediatric Liver Transplantation: Predictors, Protectors, and Clinical Relevance. Clinical Transplantation. https://doi.org/10.1111/ctr.70390

Vancouver

Kanaan E, Ohlsson S, Kathemann S, Prusinskas B, Tsaka S, Heinemann FM, et al. Assessment of Donor‐Specific Human Leukocyte Antigen Antibodies Following Pediatric Liver Transplantation: Predictors, Protectors, and Clinical Relevance. Clinical Transplantation. 2025. doi:10.1111/ctr.70390

BibTeX
@article{Kanaan2025,
  author = {Kanaan, Evelien and Ohlsson, Sinja and Kathemann, Simone and Prusinskas, Benas and Tsaka, Sofia and Heinemann, Falko M and Heinold, Andreas and Schulze, Maren and Pape, Lars and Lainka, Elke},
  title = {Assessment of Donor‐Specific Human Leukocyte Antigen Antibodies Following Pediatric Liver Transplantation: Predictors, Protectors, and Clinical Relevance},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70390}
}
Start for free →